Innoviva (INVA) Enterprise Value Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.27% |
| Dec 31, 2025 | -25.27% |
| Sep 30, 2025 | -2.08% |
| Jun 30, 2025 | -0.84% |
| Mar 31, 2025 | 2.25% |
| Dec 31, 2024 | 1.10% |
| Sep 30, 2024 | 1.46% |
| Jun 30, 2024 | 1.13% |
| Mar 31, 2024 | 0.24% |
| Dec 31, 2023 | -12.07% |
| Sep 30, 2023 | -27.99% |
| Jun 30, 2023 | -10.39% |
| Mar 31, 2023 | -20.95% |
| Dec 31, 2022 | -17.69% |
| Sep 30, 2022 | -12.35% |
| Jun 30, 2022 | -15.90% |
| Mar 31, 2022 | -5.01% |
| Dec 31, 2021 | 9.70% |
| Sep 30, 2021 | 20.90% |
| Jun 30, 2021 | 16.38% |
| Mar 31, 2021 | -5.58% |
| Dec 31, 2020 | 0.95% |
| Sep 30, 2020 | -15.83% |
| Jun 30, 2020 | -10.71% |
| Mar 31, 2020 | -7.33% |
| Dec 31, 2019 | -6.03% |
| Sep 30, 2019 | -1.29% |
| Jun 30, 2019 | 7.24% |
| Mar 31, 2019 | 13.42% |
| Dec 31, 2018 | 25.13% |
| Sep 30, 2018 | 36.47% |
| Jun 30, 2018 | 24.94% |
| Mar 31, 2018 | 34.43% |
| Dec 31, 2017 | 12.30% |
| Sep 30, 2017 | 9.26% |
| Jun 30, 2017 | 14.42% |
| Mar 31, 2017 | 3.24% |
| Dec 31, 2016 | 8.99% |
| Sep 30, 2016 | 10.89% |
| Jun 30, 2016 | 11.53% |
| Mar 31, 2016 | -2.61% |
| Dec 31, 2015 | 9.56% |
| Sep 30, 2015 | -26.72% |
| Jun 30, 2015 | -26.88% |
| Dec 31, 2014 | -38.29% |